Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis

Figure 2

Osteoarthritis pain intensity in the target knee. (a) Percentage of patients considering their state as satisfactory according to Patient Acceptable Symptom State (PASS) at weeks 2, 4, 8, and 13. **P < 0.01; ***P < 0.001 versus placebo logistic regression model adjusted for multiple comparisons. (b) Kaplan-Meier estimate of the probability of first sustained satisfaction with treatment maintained until week 13 according to PASS. P < 0.001 versus placebo for all active treatments using both log-rank and Wilcoxon tests except for lumiracoxib with initial dose versus placebo using Wilcoxon (P < 0.0001).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us